A Study to Evaluate Lumasiran in Patients With Advanced Primary

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00875823` - International Registry for Primary Hyperoxaluria	N/A
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Completed	`NCT02340689` - Primary Hyperoxaluria Mutation Genotyping/Phenotyping
Completed	`NCT00638703` - Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients	Phase 2/Phase 3
Recruiting	`NCT06065852` - National Registry of Rare Kidney Diseases
Completed	`NCT03819647` - Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria	Phase 2
Recruiting	`NCT02026388` - Rare Kidney Stone Consortium Biobank
Completed	`NCT02000219` - Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis	Phase 2
Recruiting	`NCT05843851` - Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria	N/A
Recruiting	`NCT00588562` - Rare Kidney Stone Consortium Patient Registry
Completed	`NCT03391804` - Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia	Phase 2
Completed	`NCT03116685` - A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria	Phase 3
Recruiting	`NCT05107830` - Phenotyping of Primary Hyperoxaluria
Recruiting	`NCT05001269` - Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function	Phase 2
Completed	`NCT03392896` - Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria	Phase 1
Completed	`NCT02012985` - Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria	Phase 1/Phase 2
Completed	`NCT01037231` - Phase 2/3 Oxabact Study	Phase 2/Phase 3
Completed	`NCT00589225` - Primary Hyperoxaluria Mutation Genotyping	Phase 1
Completed	`NCT02124395` - Health-related Quality of Life in Rare Kidney Stone
Completed	`NCT03350451` - An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1	Phase 2

NCT number	NCT04152200
Study type	Interventional
Source	Alnylam Pharmaceuticals
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	January 21, 2020
Completion date	July 2025

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 — ILLUMINATE-C

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms